ESMO 2014: Inhibition of PARP, angiogenesis and immune checkpoints for ovarian cancer management - European Medical Journal

Continue

ESMO 2014: Inhibition of PARP, angiogenesis and immune checkpoints for ovarian cancer management

Oncology

At ESMO 2014, Prof Jonathan Ledermann (University College London, UK) provides an update on the management of ovarian cancer, including maintenance therapy with the poly ADP-ribose polymerase (PARP) inhibitor, olaparib, for BRCA-mutated ovarian cancer; anti-angiogenic agents, such as cediranib; and immunomodulatory drugs, such as immune checkpoint inhibitors.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given